Evotec SE (EVO) Income from Non-Controlling Interests (2009 - 2019)
Evotec SE (EVO) reported Income from Non-Controlling Interests of -$933956.4 for Q4 2019, down 169684.9% sequentially from -$550.08 in Q3 2010.
Evotec SE (EVO) Income from Non-Controlling Interests (2009 - 2019) Analysis & Trends
Evotec SE (EVO) has 3 years of Income from Non-Controlling Interests data on file, last reported at -$933956.4 in Q4 2019.
- For the quarter ending Q4 2019, Income from Non-Controlling Interests changed N/A year-over-year to -$933956.4; the trailing twelve-month figure through Dec 2019 stood at -$934255.1 (changed N/A YoY), and the FY2019 full-year result was -$945219.1, changed N/A from the prior year.
- Income from Non-Controlling Interests eased to -$933956.4 in Q4 2019, from -$550.08 in the prior quarter.
- In the past five years, Income from Non-Controlling Interests ranged from a high of -$933956.4 in Q4 2019 to a low of -$933956.4 in Q4 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | - |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | - |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 395,346.10 |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | - |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | -12.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | - |
| 10 | Evotec SE | 351.60 Mn | 351.08 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2019 | -933,956.40 |
| Sep 30, 2010 | -550.08 |
| Jun 30, 2010 | 200.15 |
| Mar 31, 2010 | 51.23 |
| Dec 31, 2009 | 118,138.74 |
| Jun 30, 2009 | 247,819.99 |
| Mar 31, 2009 | 9.89 |